Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price

Michaeli, Julia Caroline; Michaeli, Thomas; Trapani, Dario; Albers, Sebastian; Dannehl, Dominik; Wuerstlein, Rachel; Michaeli, Daniel Tobias

dc.contributor.author	Dannehl, Dominik
dc.date.accessioned	2025-06-17T09:46:56Z
dc.date.available	2025-06-17T09:46:56Z
dc.date.issued	2024
dc.identifier.issn	1340-6868
dc.identifier.uri	http://hdl.handle.net/10900/166832
dc.language.iso	en	de_DE
dc.publisher	Tokyo : Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s12282-024-01634-x	de_DE
dc.subject.ddc	610	de_DE
dc.title	Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250203000000_01204
utue.publikation.seiten	1144-1155	de_DE
utue.personen.roh	Michaeli, Julia Caroline
utue.personen.roh	Michaeli, Thomas
utue.personen.roh	Trapani, Dario
utue.personen.roh	Albers, Sebastian
utue.personen.roh	Dannehl, Dominik
utue.personen.roh	Wuerstlein, Rachel
utue.personen.roh	Michaeli, Daniel Tobias
dcterms.isPartOf.ZSTitelID	Breast Cancer	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	31	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE